{"id":"epoetin-alfa-once-every-two-weeks","safety":{"commonSideEffects":[{"rate":"20-30","effect":"Hypertension"},{"rate":"10-20","effect":"Headache"},{"rate":"10-15","effect":"Arthralgia"},{"rate":"5-10","effect":"Fatigue"},{"rate":"1-5","effect":"Thrombotic events (venous thromboembolism)"},{"rate":"<1","effect":"Pure red cell aplasia"}]},"_chembl":{"chemblId":"CHEMBL1201565","moleculeType":"Protein"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Epoetin alfa is a glycoprotein that mimics endogenous erythropoietin, a hormone that regulates red blood cell production. By binding to erythropoietin receptors on erythroid progenitor cells in the bone marrow, it promotes their proliferation, differentiation, and maturation into mature red blood cells. This increases hemoglobin levels and oxygen-carrying capacity in patients with anemia.","oneSentence":"Epoetin alfa is a recombinant erythropoietin that stimulates red blood cell production by binding to erythropoietin receptors on bone marrow progenitor cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:11:15.577Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Anemia associated with chronic kidney disease"},{"name":"Anemia in patients with cancer receiving chemotherapy"},{"name":"Anemia in patients undergoing elective surgery"}]},"trialDetails":[{"nctId":"NCT07025460","phase":"PHASE4","title":"Darbepoetin Alfa Once Monthly Dosing Schedule Maintains Hemoglobin Concentration Comparable to Every 2 Weeks Dosing Schedule in Advanced Chronic Kidney Disease Patients Not on Dialysis: A Multicenter, Phase 4 Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gangnam Severance Hospital","startDate":"2019-12-19","conditions":"Chronic Kidney Disease","enrollment":40},{"nctId":"NCT01196715","phase":"PHASE3","title":"Comparison Study of Standard Care Against Combination of Growth Factors Agents for Low-risk Myelodysplastic Syndromes","status":"COMPLETED","sponsor":"Barts & The London NHS Trust","startDate":"2010-11-01","conditions":"Myelodysplastic Syndrome","enrollment":360},{"nctId":"NCT02278341","phase":"PHASE3","title":"Roxadustat in the Treatment of Anemia in End Stage Renal Disease (ESRD) Patients on Stable Dialysis","status":"COMPLETED","sponsor":"Astellas Pharma Europe B.V.","startDate":"2014-11-21","conditions":"Anemia, End Stage Renal Disease (ESRD)","enrollment":838},{"nctId":"NCT02021318","phase":"PHASE3","title":"Roxadustat in the Treatment of Anemia in Chronic Kidney Disease (CKD) Patients, Not on Dialysis, in Comparison to Darbepoetin Alfa","status":"COMPLETED","sponsor":"Astellas Pharma Europe B.V.","startDate":"2014-03-12","conditions":"Anemia in Chronic Kidney Disease in Non-dialysis Patients","enrollment":616},{"nctId":"NCT03446612","phase":"PHASE2","title":"Anemia Study in Chronic Kidney Disease (CKD) : Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat -Forearm Blood Flow (ASCEND-FBF)","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2019-01-10","conditions":"Anaemia","enrollment":6},{"nctId":"NCT05699109","phase":"","title":"Erythropoiesis Stimulating Agents for Anemia Management in Egyptian Hemodialysis Patients","status":"COMPLETED","sponsor":"Helwan University","startDate":"2021-01-01","conditions":"Anemia of Chronic Kidney Disease, Chronic Renal Failure, Chronic Renal Failure Anemia","enrollment":127},{"nctId":"NCT00436748","phase":"PHASE3","title":"Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease","status":"TERMINATED","sponsor":"Amgen","startDate":"2008-09-16","conditions":"Anemia, Chronic Kidney Disease, Kidney Disease","enrollment":116},{"nctId":"NCT00358215","phase":"PHASE3","title":"RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial","status":"COMPLETED","sponsor":"Amgen","startDate":"2006-06-01","conditions":"Heart Failure, Anemia, Cardiovascular Disease","enrollment":2278},{"nctId":"NCT00514813","phase":"PHASE4","title":"Dynepo Long-Term Safety Study","status":"TERMINATED","sponsor":"Shire","startDate":"2007-06-06","conditions":"Anemia, Kidney Failure, Chronic","enrollment":152},{"nctId":"NCT03543657","phase":"PHASE3","title":"Maintenance Treatment of Renal Anemia in Dialysis Subjects","status":"COMPLETED","sponsor":"Bayer","startDate":"2018-06-23","conditions":"Anemia, Renal Insufficiency, Chronic","enrollment":229},{"nctId":"NCT03350321","phase":"PHASE3","title":"A Study of Molidustat for Correction of Renal Anemia in Non-dialysis Subjects","status":"COMPLETED","sponsor":"Bayer","startDate":"2017-12-12","conditions":"Anemia, Renal Insufficiency, Chronic","enrollment":162},{"nctId":"NCT04464850","phase":"PHASE3","title":"Intravenous Versus Oral Iron Therapy in Hemodialysis Patients","status":"UNKNOWN","sponsor":"Chiang Mai University","startDate":"2020-07-29","conditions":"Hemodialysis Complication, Anemia, Iron Deficiency Anemia","enrollment":124},{"nctId":"NCT00070382","phase":"PHASE3","title":"Darbepoetin Alfa Compared With Epoetin Alfa in Treating Anemia in Patients Receiving Chemotherapy for Cancer","status":"COMPLETED","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2003-08","conditions":"Anemia, Leukemia, Lymphoma","enrollment":14},{"nctId":"NCT00773513","phase":"PHASE4","title":"A Study to Assess All-Cause Mortality and Cardiovascular Morbidity in Participants With Chronic Kidney Disease (CKD) on Dialysis and Those Not on Renal Replacement Therapy Receiving Methoxy Polyethylene Glycol-Epoetin Beta (Mircera) or Reference Erythropoietin Stimulating Agents (ESAs)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2008-12-12","conditions":"Chronic Renal Anemia","enrollment":2825},{"nctId":"NCT00048048","phase":"PHASE2","title":"A Study of Mircera in Anemic Patients With Chronic Kidney Disease Not Yet on Dialysis.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2002-03","conditions":"Anemia","enrollment":65},{"nctId":"NCT02049346","phase":"PHASE4","title":"Comparison Among Erythropoietin Stimulating Agents","status":"COMPLETED","sponsor":"Hamad Medical Corporation","startDate":"2012-03","conditions":"Anemia of End Stage Renal Disease","enrollment":327},{"nctId":"NCT00258440","phase":"NA","title":"Epoetin Alfa in Treating Patients With Anemia Who Are Undergoing Chemotherapy for Cancer","status":"TERMINATED","sponsor":"OHSU Knight Cancer Institute","startDate":"2003-05","conditions":"Anemia, Fatigue, Unspecified Adult Solid Tumor, Protocol Specific","enrollment":7},{"nctId":"NCT00394953","phase":"PHASE3","title":"A Study of Mircera for the Maintenance Treatment of Anemia in Dialysis Patients","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2006-12","conditions":"Anemia","enrollment":490},{"nctId":"NCT00077610","phase":"PHASE3","title":"A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2004-02","conditions":"Anemia","enrollment":673},{"nctId":"NCT00364832","phase":"PHASE2","title":"A Study of Subcutaneous (sc) Mircera in Dialysis Patients With Chronic Renal Anemia.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2001-10","conditions":"Anemia","enrollment":137},{"nctId":"NCT00048035","phase":"PHASE2","title":"A Study of Intravenous (iv) Mircera in Hemodialysis Patients With Chronic Renal Anemia","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2002-03","conditions":"Anemia","enrollment":91},{"nctId":"NCT00081471","phase":"PHASE3","title":"A Study of Mircera in the Treatment of Anemia in Patients With Chronic Kidney Disease Not on Dialysis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2004-06","conditions":"Anemia","enrollment":324},{"nctId":"NCT00077597","phase":"PHASE3","title":"A Study of Mircera for the Treatment of Anemia in Dialysis Patients","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2004-02","conditions":"Anemia","enrollment":182},{"nctId":"NCT00559273","phase":"PHASE3","title":"A Study of Subcutaneous Mircera Once Monthly in the Treatment of Anemia in Participants With Chronic Kidney Disease Not on Dialysis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2007-12","conditions":"Renal Anemia, Chronic","enrollment":307},{"nctId":"NCT00605345","phase":"PHASE3","title":"A Study Comparing Subcutaneous Mircera and Darbepoetin Alfa for Maintenance Treatment of Anemia in Kidney Transplant Recipients.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2007-12","conditions":"Anemia","enrollment":71},{"nctId":"NCT00446602","phase":"PHASE2","title":"A Phase 2 Study to Evaluate the Safety and Effectiveness of Once Weekly or Once Every Two Week Dosing of Epoetin Alfa in Anemic Patients With Low- or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)","status":"WITHDRAWN","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"","conditions":"Myelodysplastic Syndromes, Anemia","enrollment":""},{"nctId":"NCT00058331","phase":"PHASE3","title":"Epoetin Alfa in Treating Anemia in Patients With Solid Tumors","status":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2003-06","conditions":"Anemia, Leukemia, Lymphoma","enrollment":365},{"nctId":"NCT01695746","phase":"","title":"An Observational Study of Mircera (Methoxy Polyethylene Glycol-Epoetin Beta) in Stage III-IV Chronic Kidney Disease Patients Not on Dialysis With Renal Anemia","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2011-08","conditions":"Anemia","enrollment":108},{"nctId":"NCT00077623","phase":"PHASE3","title":"A Study of Subcutaneous Mircera for the Treatment of Anemia in Dialysis Patients.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2004-03","conditions":"Anemia","enrollment":572},{"nctId":"NCT00869856","phase":"PHASE3","title":"Study to Evaluate the Efficacy, Safety and Immunogenicity of Subcutaneous HX575 in the Treatment of Anemia Associated With Chronic Kidney Disease (SWEEP)","status":"WITHDRAWN","sponsor":"Sandoz","startDate":"2009-04","conditions":"Anemia, Chronic Renal Insufficiency","enrollment":""},{"nctId":"NCT00440557","phase":"PHASE3","title":"An Efficacy and Safety Study of Epoetin Alfa for Initiation and Maintenance Treatment of Patients With Anemia Associated With Chronic Kidney Disease","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2006-09","conditions":"Anemia","enrollment":375},{"nctId":"NCT00440466","phase":"PHASE3","title":"PROCRIT Extended Dosing For Maintenance of Hemoglobin in Pre-Dialysis CKD Patients","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2007-07","conditions":"Anemia, Renal Diseases","enrollment":430},{"nctId":"NCT00989092","phase":"PHASE2","title":"Darbepoetin Alfa and Anemia of Cancer","status":"TERMINATED","sponsor":"Amgen","startDate":"2002-05","conditions":"Anemia, Anemia of Cancer, Cancer","enrollment":287},{"nctId":"NCT00386152","phase":"PHASE2","title":"A Study Comparing Two Different PROCRIT Doses to a Dose of ARANESP in Anemic Cancer Patients Receiving Chemotherapy","status":"TERMINATED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2006-11","conditions":"Neoplasms, Anemia, Cancer","enrollment":235},{"nctId":"NCT00148421","phase":"PHASE3","title":"Study for the Treatment of Anemia in Patients With Non-myeloid Malignancies Receiving Multicycle Chemotherapy.","status":"COMPLETED","sponsor":"Amgen","startDate":"","conditions":"Anemia","enrollment":""},{"nctId":"NCT00598273","phase":"PHASE3","title":"Safety & Efficacy of Peginesatide for the Treatment of Anemia in Participants With Chronic Renal Failure Not on Dialysis","status":"COMPLETED","sponsor":"Affymax","startDate":"2007-10","conditions":"Chronic Renal Failure, Chronic Kidney Disease, Anemia","enrollment":490},{"nctId":"NCT00598442","phase":"PHASE3","title":"Safety and Efficacy of Peginesatide for the Treatment of Anemia in Participants With Chronic Renal Failure Not on Dialysis","status":"COMPLETED","sponsor":"Affymax","startDate":"2007-11","conditions":"Chronic Renal Failure, Chronic Kidney Disease, Anemia","enrollment":493},{"nctId":"NCT00442702","phase":"PHASE3","title":"A Study of Subcutaneous Mircera in Patients With Chronic Kidney Disease, Not on Dialysis.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2007-09","conditions":"Anemia","enrollment":228},{"nctId":"NCT00454246","phase":"PHASE3","title":"A Study of Mircera in Hemoglobin Control of Patients Transitioning to Dialysis.","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2007-04","conditions":"Anemia","enrollment":111},{"nctId":"NCT00246298","phase":"PHASE2","title":"A Study to Assess the Effectiveness of PROCRIT (Epoetin Alfa) Dosing Every 2 Weeks Versus Once a Week in Anemic HIV-infected Patients","status":"TERMINATED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2005-10","conditions":"Anemia, HIV","enrollment":31},{"nctId":"NCT00306267","phase":"PHASE2","title":"A Study of PROCRIT (Epoetin Alfa) 80,000 Units (U) Once Every Four Weeks (Q4W) vs. 40,000 U Once Every Two Weeks (Q2W) in Cancer Patients Not Receiving Chemotherapy","status":"TERMINATED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2006-03","conditions":"Anemia, Cancer, Epoetin Alfa","enrollment":61},{"nctId":"NCT00388336","phase":"PHASE2","title":"PROCRIT (Epoetin Alfa) 60,000 Units Administered Once Every Two Weeks in Anemic Cancer Patients Who Are Not Receiving Chemotherapy or Radiation Therapy","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2004-02","conditions":"Anemia, Neoplasms","enrollment":57},{"nctId":"NCT00436995","phase":"PHASE3","title":"Extension From Weekly to Once Every Other Week Darbepoetin Alfa Administration in Subjects With Chronic Kidney Disease Receiving Dialysis","status":"COMPLETED","sponsor":"Amgen","startDate":"2006-04","conditions":"Chronic Kidney Disease","enrollment":114},{"nctId":"NCT00368901","phase":"PHASE4","title":"STAAR-2 Clinical Study","status":"COMPLETED","sponsor":"Amgen","startDate":"2002-01","conditions":"Chronic Kidney Disease, Chronic Renal Insufficiency, Kidney Disease","enrollment":618},{"nctId":"NCT00369772","phase":"PHASE4","title":"STAAR-1 Clinical Study","status":"COMPLETED","sponsor":"Amgen","startDate":"2002-02","conditions":"Chronic Kidney Disease, Chronic Renal Insufficiency, Kidney Disease","enrollment":2000},{"nctId":"NCT00526929","phase":"PHASE2","title":"Fixed Dose NESP Study in Subjects With CRI","status":"COMPLETED","sponsor":"Amgen","startDate":"2000-05","conditions":"Pre-Dialysis","enrollment":75},{"nctId":"NCT00234143","phase":"PHASE2, PHASE3","title":"Erythropoietin (EPO) and Granulocyte-Colony Stimulating Factor (G-CSF) for Low-Risk Myelodysplastic Syndromes (MDS)","status":"UNKNOWN","sponsor":"St. Bartholomew's Hospital","startDate":"2004-10","conditions":"Myelodysplastic Syndromes","enrollment":360},{"nctId":"NCT00121602","phase":"PHASE3","title":"Efficacy Study: Darbepoetin Alfa for the Treatment of Anemia in Patients With Chronic Kidney Disease","status":"COMPLETED","sponsor":"Amgen","startDate":"2005-03","conditions":"Anemia, Kidney Disease","enrollment":446},{"nctId":"NCT00119587","phase":"PHASE3","title":"Darbepoetin Alfa Treatment of Anemia in Hemodialysis Subjects","status":"COMPLETED","sponsor":"Amgen","startDate":"2002-08","conditions":"Anemia","enrollment":""},{"nctId":"NCT00349960","phase":"NA","title":"Epoetin Dosing Regimens in Haemodialysis","status":"COMPLETED","sponsor":"Romanian Society of Nephrology","startDate":"2004-03","conditions":"Hemodialyzed Patients, Epoetin Treatment","enrollment":200}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":6,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["PROCRIT"],"phase":"phase_3","status":"active","brandName":"Epoetin alfa once every two weeks","genericName":"Epoetin alfa once every two weeks","companyName":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","companyId":"johnson-johnson-pharmaceutical-research-development-l-l-c","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Epoetin alfa is a recombinant erythropoietin that stimulates red blood cell production by binding to erythropoietin receptors on bone marrow progenitor cells. Used for Anemia associated with chronic kidney disease, Anemia in patients with cancer receiving chemotherapy, Anemia in patients undergoing elective surgery.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}